ADMA Biologics Q4 2019 Earnings Report
Key Takeaways
ADMA Biologics reported a significant increase in revenue for Q4 2019, driven by the commercial sales of ASCENIV and the relaunch of BIVIGAM. The company also strengthened its balance sheet through a public offering, leading to an improved working capital position.
Total revenues for Q4 2019 were $12.0 million, a 197% increase over Q4 2018.
ASCENIV sales started in October 2019, contributing to the revenue increase.
The commercial relaunch of BIVIGAM occurred in August 2019, also boosting revenue.
Net loss for Q4 2019 decreased to $10.6 million, compared to $18.0 million in Q4 2018.
ADMA Biologics
ADMA Biologics
Forward Guidance
The press release contains forward-looking statements regarding future revenues, demand for therapeutic products, fractionation plant turnaround, expansion of plasma collection center network, and research and development activities.